Tally Health raises $10 million to make science-backed longevity more accessible – AlleyWatch

The United States spends twice as much on health care as any other country, yet life expectancy is declining as a result of a combination of factors such as COVID, drug overdoses, and accidental injuries. There is an emerging science of longevity that looks at aging as a modifiable process that looks at not just genes, but epigenetics—how genes are influenced by environment and behavior to extend lifespan. tally health is a consumer-focused biotechnology company that takes a holistic approach to extending life. Offered as a membership program, the company offers quarterly epigenetic tests to understand your biological age and whether your body is more susceptible to certain conditions at any given time. Based on Profile findings, Tully also provides handpicked recommendations to improve cellular health and personalized supplements to address metabolic health. All supplements are clinically developed. vegan, non-GMO, allergen-free, gluten-free and made without preservatives.

alley watch I caught up with the CEO of Tally Health melanie goldie To learn more about the business, the company’s strategic plans, recent funding rounds and more…

Who was your investor and how much did you raise? Seed, Series A, B, etc.?

We are pleased to have closed our $10M Series Seed Funding shortly after our commercial launch in February.led the round Forerunner Ventures, additional participation by L. Cattertonwhich nurtured the company and helped initially. G9 VenturesIn addition, including celebrities, John Legend, Chrissy Teigen, Pedro Pascal, Shonda Rhimes, Kevin Hart, Rich Rolle, Whitney Cummings, and Zac Efron I personally invest in a company.

What products or services does Tally Health offer?

Tally Health is a consumer biotechnology company co-founded by world-renowned longevity scientists. Dr. David Sinclair and serial entrepreneur Whitney Caseyventure partner L. Catterton. Proprietary next-generation trained to leverage decades of clinical research to predict an individual’s epigenetic age and take into account differences in lifestyle factors such as sleep, diet, exercise and stress developed an epigenetic clock. We then provide personalized recommendations to help members improve their overall health at the cellular level, as well as proprietary longevity supplements designed to address the well-established hallmarks of aging. The platform provides consumers with a comprehensive system to measure, improve, and re-measure to track their progress over time.

What inspired you to start Tally Health?

We believe that aging is a treatable disease. But you can’t change what you can’t measure. We initially set out to create the most accurate epigenetic age test, but soon expanded it to a larger platform to help people discover ways to improve their health. , with plans customized for them. credit score”, you also need to know what to do about it.

How is Tally Health different?

Tally changes the way we think about aging and revolutionizes the way we use biological age as a metric. With unique science-backed supplements, personalized insights, and actionable lifestyle changes to combat aging, we’re helping users manage their health and future like never before.

Tally is particularly unique compared to other at-home epigenetic age tests currently on the market. This is because the algorithm has been trained on the largest and most diverse consumer DNA dataset of human cheek tissue. Additionally, our tests use cheek (cheek) swabs, which are less painful, more convenient, and less stain-resistant than saliva or blood.

What is Tally Health’s target market and size?

Longevity offers enormous untapped opportunities, especially in the context of its fundamental and universal importance. Everyone is getting older, and an increasingly knowledgeable and health-conscious generation has more agency over the process and ultimately a stronger motivation to live a more fulfilling life. The global longevity economy will reach a staggering $27 trillion in 2026, and the AgeTech segment alone is projected to reach $2.7 trillion by 2025.

what is your business model?

We offer a personalized, comprehensive membership platform that includes quarterly epigenetic age tests, personalized action plans and content, and comprehensive daily longevity supplements. These components work together as a system that allows users to track their progress over time.

What factors in your business are driving investors to write you checks?

Investor participation was driven by genuine demand for longevity, science-backed consumer innovation. Global consumer interest in assessing health through the lens of longevity is growing and previously complex, stigmatized and overlooked by evolving consumer aspirations and values. There is a growing understanding of how the health sector is gaining new importance.

What milestones do you plan to achieve in the next six months?

We are actively developing additional features and technology integrations to continue providing value-added features and customizations to our members. We have many exciting R&D initiatives in our pipeline. And we continue to bring new members to our community.

What advice can you give to New York companies that haven’t injected fresh capital into their banks?

Confidently understand cash runways and the biggest drivers of leverage in your operations in real-time to help you make agile, fast and informed decisions. Also, anyone who has raised money before knows that fundraising always takes longer than you might think. Therefore, please allow extra time in your schedule.

What is your favorite restaurant in the city?

Lure Fishbar is always a favorite, and I love Enrique Olvera’s restaurants Cosme and ATLA.

---

You’re just seconds away from signing up for Tech’s hottest list.

sign up today

---